Gabapentin and Rapidity of Recovery Among Patients Undergoing Minimally Invasive Ambulatory Uro-Oncologic Surgeries
- PMID: 38899668
- PMCID: PMC11192234
- DOI: 10.1097/UPJ.0000000000000570
Gabapentin and Rapidity of Recovery Among Patients Undergoing Minimally Invasive Ambulatory Uro-Oncologic Surgeries
Abstract
Introduction: Gabapentin has been used in enhanced recovery after surgery (ERAS) pathways for pain control for patients undergoing ambulatory uro-oncologic surgery; however, it may cause undesirable side effects. We studied the causal association between gabapentin and rapidity of recovery and perioperative pain management after minimally invasive uro-oncologic surgery.
Methods: We identified 2397 patients ≤ 65 years undergoing prostatectomies or nephrectomies between 2018 and 2022; 131 (5.5%) did not receive gabapentin. We tested the effect of gabapentin use on time of discharge and perioperative opioid consumption, respectively, using multivariable linear regression adjusting for potential confounders including age, gender, BMI, American Society of Anesthesiologists score, and surgery type.
Results: On adjusted analysis, we found no evidence of a difference in discharge time among those who did vs did not receive gabapentin (adjusted difference 0.07 hours shorter on gabapentin; 95% CI -0.17, 0.31; P = .6). There was no evidence of a difference in intraoperative opioid consumption by gabapentin receipt (adjusted difference -1.5 morphine milligram equivalents; 95% CI -4.2, 1.1; P = .3) or probability of being in the top quartile of postoperative opioid consumption within 24 hours (adjusted difference 4.2%; 95% CI -4.8%, 13%; P = .4). We saw no important differences in confounders by gabapentin receipt suggesting causal conclusions are justified.
Conclusions: Our confidence intervals did not include clinically meaningful benefits from gabapentin, when used with an ERAS protocol, in terms of length of stay or perioperative opioid use. These results support the omission of gabapentin from ERAS protocols for minimally invasive uro-oncologic surgeries.
Keywords: ambulatory surgery; gabapentin; nephrectomy; prostatectomy.
Conflict of interest statement
Similar articles
-
Enhanced Recovery Programs in an Ambulatory Surgical Oncology Center.Anesth Analg. 2021 Dec 1;133(6):1391-1401. doi: 10.1213/ANE.0000000000005356. Anesth Analg. 2021. PMID: 34784326 Free PMC article.
-
Opioid-free anesthesia within an enhanced recovery after surgery pathway for minimally invasive lumbar spine surgery: a retrospective matched cohort study.Neurosurg Focus. 2019 Apr 1;46(4):E8. doi: 10.3171/2019.1.FOCUS18645. Neurosurg Focus. 2019. PMID: 30933925
-
Intraoperative opioid and analgesic adjuvant administration practice patterns following implementation of an enhanced recovery after surgery protocol for laparoscopic donor nephrectomy.J Clin Anesth. 2022 Aug;79:110751. doi: 10.1016/j.jclinane.2022.110751. Epub 2022 Mar 22. J Clin Anesth. 2022. PMID: 35334291
-
Efficacy of perioperative gabapentin use in patients with idiopathic scoliosis undergoing fusion surgery: a systematic review and meta-analysis.Eur Spine J. 2023 Jul;32(7):2521-2532. doi: 10.1007/s00586-023-07764-8. Epub 2023 May 20. Eur Spine J. 2023. PMID: 37209210 Review.
-
Perioperative gabapentin usage in pediatric patients: A scoping review.Paediatr Anaesth. 2023 Aug;33(8):598-608. doi: 10.1111/pan.14674. Epub 2023 Apr 19. Paediatr Anaesth. 2023. PMID: 37073498 Free PMC article. Review.
References
-
- Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019;100(1):32–8. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources